EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseÜbersichtsarbeitOpen Access

Low-dose oral misoprostol for induction of labour

Chris E Philip, Nimisha Kumar, Parvin Abedi, Beng Kwang Ng, Shuchita Mundle, Jo Weeks, Andrew D Weeks, David M Haas iD

Cochrane Database of Systematic Reviews · 16.11.2026 · 2026 (11)

DOI: 10.1002/14651858.cd014484.pub2 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cochrane Database of Systematic Reviews, online erschienen am 16.11.2026. Verfasst von Chris E Philip und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Misoprostol, Labor, Induced, Oxytocics. Die Arbeit nennt 298 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RATIONALE: Oral misoprostol is a common labour induction method. This review is restricted to lower doses (initially ≤ 50 µg), as higher doses pose unacceptably high risks of uterine hyperstimulation. OBJECTIVES: To assess the benefits and harms of low-dose oral misoprostol for labour induction in women with a viable fetus in the third trimester of pregnancy, compared with other methods of labour induction. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, CINAHL, ClinicalTrials.gov and the WHO ICTRP, and checked reference lists of retrieved studies. The search date was April 2025. ELIGIBILITY CRITERIA: Randomised trials comparing low-dose oral misoprostol (≤ 50 µg initial dose) versus placebo, vaginal dinoprostone, vaginal misoprostol, oxytocin or mechanical methods, or comparing oral protocols (20 µg hourly titrated versus 25 µg two-hourly static; 20 µg to 25 µg versus 50 µg or one- to two-hourly versus four- to six-hourly). OUTCOMES: Our critical outcomes were vaginal birth within 24 hours, caesarean section and uterine hyperstimulation with fetal heart rate changes. RISK OF BIAS: We assessed the risk of bias using RoB 1. SYNTHESIS METHODS: Two authors independently screened reports, extracted data and assessed risk of bias. We synthesised results using random-effects meta-analysis, expressing effect estimates as risk ratios (RR) or mean differences (MD) and assessing heterogeneity using I². We evaluated evidence certainty using GRADE. INCLUDED STUDIES: We included 44 trials (38 from the previous version, 6 new), involving 11,795 women. SYNTHESIS OF RESULTS: Oral misoprostol versus placebo/no treatment (3 trials, 294 women) Vaginal birth within 24 hours was not reported. Oral misoprostol probably results in little or no difference in caesarean section (RR 0.73, 95% confidence interval (CI) 0.48 to 1.11; 3 trials, 294 women; moderate-certainty evidence); its effect on uterine hyperstimulation with fetal heart rate changes is uncertain (RR 5.15, 95% CI 0.25 to 105.31; 2 trials, 195 women; low-certainty evidence). Oral misoprostol versus vaginal dinoprostone (9 trials, 3188 women) Oral misoprostol may result in little or no difference in vaginal birth within 24 hours compared with vaginal dinoprostone, but the evidence is very uncertain (RR 0.94, 95% CI 0.84 to 1.05; 6 trials, 2492 women; very low-certainty evidence). It may also result in little or no difference in caesarean section (RR 0.91, 95% CI 0.80 to 1.04; 9 trials, 3185 women; low-certainty evidence) and in uterine hyperstimulation with fetal heart rate changes (RR 0.89, 95% CI 0.59 to 1.33; 7 trials, 2593 women; low-certainty evidence). Oral misoprostol versus vaginal misoprostol (20 trials, 4130 women) Oral misoprostol may result in fewer vaginal births within 24 hours (RR 0.78, 95% CI 0.63 to 0.97; 11 trials, 2771 women; low-certainty evidence), may result in little or no difference in caesarean section (RR 0.90, 95% CI 0.76 to 1.07; 20 trials, 4128 women; low-certainty evidence) and may result in less uterine hyperstimulation with fetal heart rate changes (RR 0.70, 95% CI 0.52 to 0.95; 16 trials, 3431 women; low-certainty evidence). Oral misoprostol versus intravenous oxytocin (4 trials, 426 women) Oral misoprostol may result in little or no difference in vaginal birth within 24 hours, but the evidence is very uncertain (RR 1.04, 95% CI 0.90 to 1.21; 2 trials, 210 women; very low-certainty evidence), in caesarean section (RR 0.87, 95% CI 0.58 to 1.30; 4 trials, 426 women; low-certainty evidence) and in uterine hyperstimulation with fetal heart rate changes (RR 0.72, 95% CI 0.17 to 3.08; 2 trials, 248 women; very low-certainty evidence). Oral misoprostol versus mechanical methods (9 trials, 3794 women) Oral misoprostol may result in little or no difference in vaginal birth within 24 hours, but the evidence is very uncertain (RR 1.41, 95% CI 0.97 to 2.05; 5 trials, 1273 women; very low-certainty evidence), probably reduces caesarean section (RR 0.85, 95% CI 0.76 to 0.95; 9 trials, 3746 women; moderate-certainty evidence) and probably increases uterine hyperstimulation with fetal heart rate changes (RR 1.60, 95% CI 1.01 to 2.54; 6 trials, 3275 women; moderate-certainty evidence). Oral misoprostol 20 µg hourly titrated versus 25 µg two-hourly static (1 trial, 146 women) Oral misoprostol 20 µg hourly titrated may result in little or no difference in vaginal birth within 24 hours compared with oral misoprostol 25 µg two-hourly static, but the evidence is very uncertain (RR 0.98, 95% CI 0.77 to 1.24; 1 trial, 146 women; very low-certainty evidence) and may increase caesarean section (RR 2.83, 95% CI 1.18 to 6.78; 1 trial, 146 women; low-certainty evidence); its effect on uterine hyperstimulation with fetal heart rate changes is uncertain (RR 3.00, 95% CI 0.12 to 72.45; 1 trial, 146 women; very low-certainty evidence). Oral misoprostol 20 µg to 25 µg versus 50 µg (1 trial, 64 women) The use of 20 µg to 25 µg versus 50 µg of oral misoprostol may result in little to no difference in vaginal birth within 24 hours (RR 0.60, 95% CI 0.31 to 1.17; 1 trial, 64 women; very low-certainty evidence) or in caesarean section (RR 1.31, 95% CI 0.77 to 2.22; 1 trial, 64 women; very low-certainty evidence) but the evidence is very uncertain; no cases of uterine hyperstimulation with fetal heart rate changes were reported. Oral misoprostol one- to two-hourly versus four- to six-hourly (1 trial; 64 women) This comparison is based on the same single trial as the previous comparison, and the findings are therefore identical. AUTHORS' CONCLUSIONS: Low-dose oral misoprostol has similar effects to other commonly used induction methods across most key outcomes. Certainty of the evidence ranged from very low to moderate, mainly due to imprecision and inconsistency. Compared with placebo, vaginal dinoprostone and intravenous oxytocin, oral misoprostol may result in little or no difference in vaginal birth within 24 hours or caesarean section. Compared with vaginal misoprostol, oral misoprostol may reduce uterine hyperstimulation with fetal heart rate changes, but may also reduce vaginal births within 24 hours. Compared with mechanical methods, oral misoprostol probably reduces caesarean section, although it probably increases uterine hyperstimulation with fetal heart rate changes. FUNDING: This Cochrane review had no dedicated funding. REGISTRATION: Registration: Protocol PROSPERO (2018) CRD42018092212 Original review (2021) DOI: 10.1002/14651858.CD014484.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MisoprostolLabor, InducedOxytocicsHumansFemalePregnancyAdministration, OralRandomized Controlled Trials as TopicCesarean SectionDinoprostoneAdministration, IntravaginalHeart Rate, FetalOxytocinPregnancy Trimester, Third

Substanzen

MisoprostolOxytocicsDinoprostoneOxytocin

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut, USA.
  • Midwifery Department, Menopause Andropause Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Department of Obstetrics and Gynaecology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
  • Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, Nagpur, Nagpur, India.
  • Department of Women's and Children's Health, The University of Liverpool, Liverpool, UK.

ORCID-Profile: David M Haas

Zitieren

APA

Philip, C. E., Kumar, N., Abedi, P., Ng, B. K., Mundle, S., Weeks, J., Weeks, A. D., & Haas, D. M. (2026). Low-dose oral misoprostol for induction of labour. Cochrane Database of Systematic Reviews, 2026(11). https://doi.org/10.1002/14651858.cd014484.pub2

Vancouver

Philip CE, Kumar N, Abedi P, Ng BK, Mundle S, Weeks J, et al. Low-dose oral misoprostol for induction of labour. Cochrane Database of Systematic Reviews. 2026;2026(11). doi:10.1002/14651858.cd014484.pub2

BibTeX
@article{Philip2026,
  author = {Philip, Chris E and Kumar, Nimisha and Abedi, Parvin and Ng, Beng Kwang and Mundle, Shuchita and Weeks, Jo and Weeks, Andrew D and Haas, David M},
  title = {Low-dose oral misoprostol for induction of labour},
  journal = {Cochrane Database of Systematic Reviews},
  year = {2026},
  volume = {2026},
  number = {11},
  doi = {10.1002/14651858.cd014484.pub2}
}
Kostenlos starten →